These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 1963118)

  • 1. Immunogenicity of oral poliomyelitis vaccine (OPV) against variants of wild poliovirus type 3.
    Böthig B; Danes L; Dittmann S
    Bull World Health Organ; 1990; 68(5):597-600. PubMed ID: 1963118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity of oral poliovirus vaccine administered in mass campaigns versus routine immunization programmes.
    Richardson G; Linkins RW; Eames MA; Wood DJ; Campbell PJ; Ankers E; Deniel M; Kabbaj A; Magrath DI; Minor PD
    Bull World Health Organ; 1995; 73(6):769-77. PubMed ID: 8907770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anomalous observations on IPV and OPV vaccination.
    John TJ
    Dev Biol (Basel); 2001; 105():197-208. PubMed ID: 11763328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of efficacy of a live oral poliovirus vaccine for virulent Sabin-like poliovirus 1 strains in Japan.
    Iwai M; Nakayama T; Matsuura K; Hasegawa S; Ando S; Obara M; Nagai Y; Yoshida H; Horie H
    Acta Virol; 2006; 50(2):139-43. PubMed ID: 16808333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral poliovaccine: will it help eradicate polio or cause the next epidemic?
    Shulman LM; Manor Y; Sofer D; Swartz T; Mendelson E
    Isr Med Assoc J; 2006 May; 8(5):312-5. PubMed ID: 16805227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interrupting wild poliovirus transmission using oral poliovirus vaccine: environmental surveillance in high-risks area of India.
    Chowdhary R; Dhole TN
    J Med Virol; 2008 Aug; 80(8):1477-88. PubMed ID: 18551602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Asymptomatic wild-type poliovirus infection in India among children with previous oral poliovirus vaccination.
    Grassly NC; Jafari H; Bahl S; Durrani S; Wenger J; Sutter RW; Bruce Aylward R
    J Infect Dis; 2010 May; 201(10):1535-43. PubMed ID: 20367459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The spread of the wild Poliovirus in the rural environment, the case of the Adzopé health district, Côte d'Ivoire].
    Akoua-Koffi CG; Nekouressi G; Tieoulou L; Guillot S; Faye-Kette H; Ehouman A
    Bull Soc Pathol Exot; 2004 May; 97(2):87-90. PubMed ID: 15255346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lessons from Cuba: mass campaign administration of trivalent oral poliovirus vaccine and seroprevalence of poliovirus neutralizing antibodies.
    Mas Lago P; Ramon Bravo J; Andrus JK; Comellas MM; Galindo MA; de Quadros CA; Bell E
    Bull World Health Organ; 1994; 72(2):221-5. PubMed ID: 8205641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of a two-dose administration of live oral poliovirus vaccine for wild and virulent vaccine-derived poliovirus type 1, 2, 3 strains in Japan.
    Iwai M; Takizawa T; Nakayama T; Matsuura K; Yoshida H; Hasegawa S; Obara M; Horimoto E; Kurata T; Horie H
    Scand J Infect Dis; 2008; 40(3):247-53. PubMed ID: 17907043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The maintaining of the active laboratory-based surveillance of the acute flaccid paralysis (AFP) cases in Romania in the framework of the strategic plan of the global polio eradication initiative.
    Băicuş A; Persu A; Combiescu M; Aubert-Combiescu A
    Roum Arch Microbiol Immunol; 2007; 66(1-2):44-50. PubMed ID: 18928063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistence of antibodies in a population immunized with oral poliovaccine (OPV).
    Srámová H; Teplý V; Svandová E
    J Hyg Epidemiol Microbiol Immunol; 1979; 23(2):212-9. PubMed ID: 231625
    [No Abstract]   [Full Text] [Related]  

  • 13. 2001 serological survey in the Czech Republic--poliomyelitis.
    Matyásová I; Rainetová P; Cástková J
    Cent Eur J Public Health; 2003 Dec; 11 Suppl():S31-5. PubMed ID: 15080257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A comparison of the effectiveness of mass immunization campaign of trivalent oral poliovirus vaccine (TOPV) by epidemiological serosurvey. Shandong Collaborating Group for Poliomyelitis Control and Surveillance, Jinan, Shandong].
    Xu A
    Zhonghua Liu Xing Bing Xue Za Zhi; 1992 Oct; 13(5):261-4. PubMed ID: 1338626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mucosal immunity after vaccination with monovalent and trivalent oral poliovirus vaccine in India.
    Grassly NC; Jafari H; Bahl S; Durrani S; Wenger J; Sutter RW; Aylward RB
    J Infect Dis; 2009 Sep; 200(5):794-801. PubMed ID: 19624278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polio eradication: the OPV paradox.
    Dowdle WR; De Gourville E; Kew OM; Pallansch MA; Wood DJ
    Rev Med Virol; 2003; 13(5):277-91. PubMed ID: 12931339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Seroprevalence of poliovirus antibodies among children in a Dominican community--Puerto Rico, 2002.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2005 Jun; 54(23):580-1. PubMed ID: 15959453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful control of poliomyelitis by a combined OPV/IPV polio vaccine program in the West Bank and Gaza, 1978-93.
    Tulchinsky T; Abed Y; Handsher R; Toubassi N; Acker C; Melnick J
    Isr J Med Sci; 1994; 30(5-6):489-94. PubMed ID: 8034509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eradication of poliomyelitis in Cuba: a historical perspective.
    Más Lago P
    Bull World Health Organ; 1999; 77(8):681-7. PubMed ID: 10516790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Waning intestinal immunity after vaccination with oral poliovirus vaccines in India.
    Grassly NC; Jafari H; Bahl S; Sethi R; Deshpande JM; Wolff C; Sutter RW; Aylward RB
    J Infect Dis; 2012 May; 205(10):1554-61. PubMed ID: 22448007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.